These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 20153429)

  • 21. Envisioning the Future of Nanomedicines in Management and Treatment of Neurological Disorders.
    Kumar S; Singh P; Sharma S; Pottoo FH; Ali J; Baboota S
    Comb Chem High Throughput Screen; 2021; 24(10):1544-1556. PubMed ID: 33334281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the brain--surmounting or bypassing the blood-brain barrier.
    Potschka H
    Handb Exp Pharmacol; 2010; (197):411-31. PubMed ID: 20217538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in the treatment of neurodegenerative disorders employing nanotechnology.
    Modi G; Pillay V; Choonara YE
    Ann N Y Acad Sci; 2010 Jan; 1184():154-72. PubMed ID: 20146696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Targeted nanomedicine in diagnostics and therapy of neurological diseases].
    Bertalan F; László B; Attila V
    Ideggyogy Sz; 2013 May; 66(5-6):155-63. PubMed ID: 23909015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug delivery to the central nervous system: a review.
    Misra A; Ganesh S; Shahiwala A; Shah SP
    J Pharm Pharm Sci; 2003; 6(2):252-73. PubMed ID: 12935438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Precision nanomedicine in neurodegenerative diseases.
    Goldsmith M; Abramovitz L; Peer D
    ACS Nano; 2014 Mar; 8(3):1958-65. PubMed ID: 24660817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles.
    Lanza GM; Winter PM; Caruthers SD; Hughes MS; Cyrus T; Marsh JN; Neubauer AM; Partlow KC; Wickline SA
    Nanomedicine (Lond); 2006 Oct; 1(3):321-9. PubMed ID: 17716162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nucleic Acids-based Nanotherapeutics Crossing the Blood Brain Barrier.
    Nafee N; Gouda N
    Curr Gene Ther; 2017; 17(2):154-169. PubMed ID: 28494740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies.
    Loureiro JA; Gomes B; Coelho MA; do Carmo Pereira M; Rocha S
    Nanomedicine (Lond); 2014 Apr; 9(5):709-22. PubMed ID: 24827845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the Brain with Nanomedicine.
    Rueda F; Cruz LJ
    Curr Pharm Des; 2017; 23(13):1879-1896. PubMed ID: 28003011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanotechnology-empowered therapeutics targeting neurodegenerative diseases.
    Wang Z; Gonzalez KM; Cordova LE; Lu J
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1907. PubMed ID: 37248794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Internal benchmarking of a human blood-brain barrier cell model for screening of nanoparticle uptake and transcytosis.
    Ragnaill MN; Brown M; Ye D; Bramini M; Callanan S; Lynch I; Dawson KA
    Eur J Pharm Biopharm; 2011 Apr; 77(3):360-7. PubMed ID: 21236340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The blood-brain barrier: structure, function and therapeutic approaches to cross it.
    Tajes M; Ramos-Fernández E; Weng-Jiang X; Bosch-Morató M; Guivernau B; Eraso-Pichot A; Salvador B; Fernàndez-Busquets X; Roquer J; Muñoz FJ
    Mol Membr Biol; 2014 Aug; 31(5):152-67. PubMed ID: 25046533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prodrug approaches to reduce hyperexcitation in the CNS.
    Vytla D; Combs-Bachmann RE; Hussey AM; McCarron ST; McCarthy DS; Chambers JJ
    Adv Drug Deliv Rev; 2012 May; 64(7):666-85. PubMed ID: 22138074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New perspectives of nanoneuroprotection, nanoneuropharmacology and nanoneurotoxicity: modulatory role of amino acid neurotransmitters, stress, trauma, and co-morbidity factors in nanomedicine.
    Sharma HS; Sharma A
    Amino Acids; 2013 Nov; 45(5):1055-71. PubMed ID: 24022705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranasal treatment of neurodegenerative diseases and stroke.
    Gomez D; Martinez JA; Hanson LR; Frey WH; Toth CC
    Front Biosci (Schol Ed); 2012 Jan; 4(1):74-89. PubMed ID: 22202044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent prospective of surface engineered Nanoparticles in the management of Neurodegenerative disorders.
    Singh D; Kapahi H; Rashid M; Prakash A; Majeed AB; Mishra N
    Artif Cells Nanomed Biotechnol; 2016 May; 44(3):780-91. PubMed ID: 26107112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inorganic hollow nanoparticles and nanotubes in nanomedicine Part 1. Drug/gene delivery applications.
    Son SJ; Bai X; Lee SB
    Drug Discov Today; 2007 Aug; 12(15-16):650-6. PubMed ID: 17706547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The blood-brain barrier and drug delivery in the central nervous system].
    Loch-Neckel G; Koepp J
    Rev Neurol; 2010 Aug; 51(3):165-74. PubMed ID: 20645267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategies and advances in nanomedicine for targeted siRNA delivery.
    Nimesh S; Gupta N; Chandra R
    Nanomedicine (Lond); 2011 Jun; 6(4):729-46. PubMed ID: 21718181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.